A Phase IB Dose Escalation and Expansion Trial of MEK 162 With Docetaxel in Previously Treated Stage IV, Non-small Cell Lung Cancer (NSCLC)
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2016
At a glance
- Drugs Binimetinib (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 07 Jul 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 07 Jan 2016 Planned end date changed from 1 Jun 2018 to 1 Jun 2019, as reported by ClinicalTrials.gov.